A phase III study of lurbinectedin alone or in combination with irinotecan vs investigator's choice (topotecan or irinotecan) in patients with relapsed small cell lung cancer (SCLC; LAGOON trial).

Authors :: Besse, Benjamin
Paz-Ares, Luis G.
Peters, Solange
Cappuzzo, Federico
Reck, Martin
Calles, Antonio
Califano, Raffaele
Lopez-Vilariño, Jose Antonio
Veramendi, Susie
Kahatt, Carmen Maria
Zeaiter, Ali Hassan
Sands, Jacob
Source :: Journal of Clinical Oncology; 2023 Supplement 16, Vol. 41, pTPS8613-TPS8613, 1p
Publication Year :: 2023

Full Text Access

Tools